Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy

MLA

Luo MC, et al. “Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy.” Journal of Hepatocellular Carcinoma, vol. ume 10, Oct. 2023, pp. 1827–37. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.1c8fa37b1c8840bca2bc8eafc1a00765&authtype=sso&custid=ns315887.

APA

Luo MC, Wu JY, Lin ZT, Li YN, Zeng ZX, Wei SM, & Yan ML. (2023). Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy. Journal of Hepatocellular Carcinoma, ume 10, 1827–1837.

Chicago

Luo MC, Wu JY, Lin ZT, Li YN, Zeng ZX, Wei SM, and Yan ML. 2023. “Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy.” Journal of Hepatocellular Carcinoma ume 10 (October): 1827–37. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.1c8fa37b1c8840bca2bc8eafc1a00765&authtype=sso&custid=ns315887.